Document is current
Any future updates will be listed below
-
Authors
Raj-Kumar, Praveen-Kumar
Lin, Xiaoying
Liu, Tao
Sturtz, Lori A.
Gritsenko, Marina A.
Petyuk, Vladislav A.
Sagendorf, Tyler J.
Deyarmin, Brenda
Liu, Jianfang
Praveen-Kumar, Anupama
Wang, Guisong
McDermott, Jason E.
Shukla, Anil K.
Moore, Ronald J.
Monroe, Matthew E.
Webb-Robertson, Bobbie-Jo M.
Hooke, Jeffrey A.
Fantacone-Campbell, Leigh
Mostoller, Brad
Kvecher, Leonid
Kane, Jennifer
Melley, Jennifer
Somiari, Stella
Soon-Shiong, Patrick
Smith, Richard D.
Mural, Richard J.
Rodland, Karin D.
Shriver, Craig D.
Kovatich, Albert J.
Hu, Hai
-
Funding
Funding for this research was provided by:
Henry M. Jackson Foundation (W81XWH-12-2-0050, W81XWH-12-2-0050)
Uniformed Services University of the Health Sciences (HU0001-16-2-0004, HU0001-16-2-0004)
- License Information
-
More Information
Article History
Received: 12 January 2024
Accepted: 5 May 2024
First Online: 14 May 2024
Declarations
:
: We support inclusive, diverse, and equitable conduct of research.
: All authors have reviewed and provided their consent for the publication of the content presented in this manuscript.
: P.S.S. is founder and shareholder of NantOmics and ImmunityBio. H.H. is a co-founder and shareholder of miRoncol Diagnostics, Inc. Provisional patent application has been filed for the phosphopetide markers associated with the basal-like breast cancer (Application #63/587,785, filed October 04, 2023. Patent pending).
